CION Ameerpet
PET-CT is a problem-solving scan, not a routine one. It is genuinely useful in specific situations — mostly around suspected recurrence — and it is not part of the standard work-up at first diagnosis. Knowing which situation you are in explains a great deal.
PET-CT is two scans in one. The PET part detects metabolic activity: a small amount of radiolabelled glucose is injected, and tissues that are consuming glucose rapidly take up more of it and show up brightly. The CT part provides the anatomical map, so those bright areas can be located precisely.
The appeal is obvious. Cancer cells generally consume glucose faster than normal tissue, so active disease tends to light up. That makes PET-CT genuinely powerful for finding disease that anatomical imaging alone might miss, and for distinguishing active tumour from scar tissue that simply looks abnormal.
The limitation is equally important and less often explained. Anything metabolically active lights up — infection, inflammation, healing after surgery, and normal tissues such as the bowel and the ovaries during ovulation. And some tumours consume glucose slowly and barely show at all. So a bright spot is not automatically cancer, and a quiet scan does not automatically mean none.
Radiolabelled glucose is taken up by tissue consuming glucose quickly. The CT locates the bright areas.
Which makes it good at finding disease anatomical imaging might miss, and at distinguishing tumour from scar.
Infection, inflammation, healing tissue and normal bowel all take up glucose too.
PET-CT is not part of routine initial staging for ovarian cancer, and the reason is a specific technical one. Ovarian cancer spreads as thin sheets and small nodules across the peritoneal surfaces — and PET has limited spatial resolution, so deposits below a few millimetres frequently do not register. Contrast CT, which shows anatomical detail and peritoneal thickening directly, performs better for exactly this pattern of spread. Add that the bowel takes up glucose normally and sits everywhere in the abdomen, and the peritoneum becomes a genuinely difficult area for PET. It is a problem-solving tool, used for specific questions. Source: NCCN Ovarian Cancer guidelines; published imaging literature.
The distinction is fairly sharp, and knowing which column your situation falls into explains why it has or has not been arranged.
| Situation | Is PET-CT useful? | Why |
|---|---|---|
| Initial staging of newly diagnosed disease | Not routinely. | Contrast CT performs better for peritoneal spread; PET misses small deposits. |
| Characterising an ovarian mass | No. | Ultrasound and MRI do this far better. PET does not read tissue types. |
| Rising marker, normal or equivocal CT | Yes — this is its strongest use. | Can localise disease that anatomical imaging cannot resolve. |
| Distinguishing tumour from scar tissue | Often yes. | Scar is metabolically quiet; active tumour is not. |
| Assessing isolated recurrence before surgery | Frequently helpful. | Confirms whether disease really is isolated, which determines whether surgery makes sense. |
| An indeterminate lesion on CT elsewhere | Sometimes. | Can clarify whether a lesion is metabolically active. |
| Mucinous ovarian cancer | Less reliable. | These tumours often take up glucose poorly and may not light up. |
| Soon after surgery or chemotherapy | Unreliable timing. | Healing tissue and treatment effect cause false positives. Timing matters. |
*If PET-CT has been arranged for you, it is worth asking what specific question it is being asked. A scan without a clear question tends to produce findings that generate more scans.
PET-CT takes longer than a CT and has more preparation, most of it aimed at making the glucose signal interpretable.
You will be asked to fast for several hours beforehand and to avoid carbohydrates the day before. This is not routine caution — it is central to the scan working. If your blood glucose is high, the injected radiolabelled glucose competes with your own circulating glucose and tumour uptake is reduced, which can make disease invisible.
Your blood glucose is checked before the injection and the scan may be postponed if it is too high. If you have diabetes, tell the department in advance so your medication and timing can be planned properly rather than improvised on the day.
After the injection you rest quietly for about an hour while the tracer distributes. You will be asked not to talk, read, use your phone or move around — because muscles that are working take up glucose, and active muscle can obscure or mimic disease on the images.
Warmth matters too, since brown fat takes up glucose when you are cold and can produce confusing bright areas. Departments keep the room warm for this reason. It is a dull hour, and following the instructions genuinely improves the scan.
The scan takes roughly twenty to forty minutes. The scanner is a ring similar to a CT, open at both ends, so claustrophobia is less of an issue than with MRI — though you are in it for longer. You lie still, usually with arms above your head.
The radiation dose is higher than a standard CT because it combines the tracer with a CT scan. That is a real consideration and part of why PET-CT is reserved for questions it can genuinely answer rather than used routinely.
You will be mildly radioactive for a few hours. Departments generally advise drinking plenty of fluid to clear the tracer and limiting close contact with pregnant women and young children for the rest of the day. The exact advice varies and the department will give you specific instructions.
There are no lasting effects and you can eat and resume normal activity immediately. The tracer decays quickly and is cleared through the urine.
Timing is genuinely important and often overlooked. Recent surgery causes inflammation and healing that take up glucose avidly, and recent chemotherapy or radiotherapy also alters uptake. A scan done too soon produces false positives that lead to unnecessary worry and further investigation.
For this reason PET-CT is usually deferred for a period after surgery or treatment. If yours has been scheduled soon after an intervention, it is reasonable to ask whether the timing will affect interpretation.
Reports often quote an SUV — a standardised uptake value — as a number describing how avidly an area took up the tracer. Higher generally means more metabolically active, but there is no clean threshold separating cancer from inflammation, and the number should never be read in isolation.
What matters is the pattern: where the uptake is, whether it matches an anatomical abnormality on the CT component, how it compares with previous imaging, and whether it fits the clinical picture. A single bright spot on its own frequently means nothing.
This scan is most useful when it has a specific question to answer. These establish whether yours does.
A scan arranged without a clear question tends to produce incidental findings that generate more scans.
For peritoneal disease it often does it better, with less radiation and less preparation.
Too soon after surgery or chemotherapy and inflammation causes false positives. Ask whether timing affects interpretation.
Mucinous ovarian cancers often take up glucose poorly and may not light up despite active disease.
If the answer would not alter management either way, the scan may not be warranted.
Tell the department in advance so glucose control and medication timing can be planned rather than improvised.
A quiet PET-CT is reassuring but not conclusive — small peritoneal deposits and mucinous tumours can be missed. Symptoms and markers still count alongside it.
PET-CT is excellent at one job and mediocre at others. If it has been suggested, it is worth understanding what specific question it is being asked to answer.
We're never more than 30 minutes away. Same panel of specialists at every centre. Same tumour board reviews. Same NCCN protocols. Pick the closest one and call directly — or let us pick for you.
CION Ameerpet
CION Kukatpally
CION L.B. Nagar
CION Tolichowki
CION Masab Tank
CION Banjara Hills
CION Kompally
CION Balanagar
CION Siddipet
CION Sangareddy
Not sure which centre fits best? Tell us where you are — we'll suggest the closest one with the right specialists.
Help me pick the right centreTravelling for treatment? We may have a centre right where you are.
Don't see your city? Call 18002028726 — we'll find your nearest CION partner centre.
Trained at AIIMS, Tata Memorial and leading international centres. Combined 150+ years of experience. Every complex case is reviewed by 3+ of them - together.
MBBS(Gold Medal), DNB(General Medicine), DM(Medical Oncology)(Gold Medal)
MBBS, MD(General Medicine), DM(Medical Oncology)(Adyar,Chennai), ECMO, MRCP SCE(UK)
MBBS, MD (General Medicine), DrNB (Medical Oncology), ECMO, MRCP SCE (Medical Oncology) (UK)
MBBS (AIIMS), MS (Surgery) (AIIMS), DNB (Surgical Oncology), MRCS (Edinburgh)
MBBS, MS(General Surgery), M.Ch(Surgical Oncology), FMAS, FARIS(Ongoing)
MBBS, MS (General Surgery), DrNB (Surgical Oncology), FALS Oncology
Want a specific doctor for your case? Mention them when booking.
Book Free ConsultationShare your name and number — we'll call you back within 30 minutes to schedule your consultation.
No referral needed and no cost for the first consultation. PET-CT is arranged through partner imaging centres and may be billed there.
PET-CT carries an aura of being the most advanced scan available, which makes it easy to assume that having one means better care and not having one means something is being missed. Neither is true. It is a specialised tool that answers certain questions well and others poorly, and using it where CT would do the job better is not thoroughness.
Your first consultation at CION is free and runs to about 45 minutes. Bring your existing imaging reports. Where PET-CT has been suggested elsewhere, the useful conversation is what specific question it is being asked to answer and whether it is the right test for it — and where it genuinely is the right test, we will say so plainly.
We should be clear about delivery. PET-CT is arranged through partner imaging centres and may be billed there — it is not delivered in-house at CION, and we state that upfront rather than leaving it to be discovered later. Chemotherapy and maintenance therapy are delivered in-house across 35+ centres in Telangana and Andhra Pradesh, alongside genetic counselling and BRCA and HRD testing. Surgery is coordinated with specialist gynaecologic-oncology partner centres.
Arranged through partner imaging centres and may be billed there. We say so upfront.
Free and unhurried. Long enough to work out which scan answers your actual question.
For peritoneal disease, contrast CT frequently outperforms PET with less radiation and preparation.
Delivered across 35+ centres in Telangana and Andhra Pradesh, near where you live.
This is the situation PET-CT is genuinely built for, and it is worth describing because it is where most women encounter it. After treatment, a CA-125 begins to rise across successive tests. A conventional CT is done and shows nothing definite — or shows something small and ambiguous that could be anything.
That is an uncomfortable place to be. Something appears to be happening, and nobody can point to where. PET-CT can sometimes localise disease that anatomical imaging cannot resolve, because it looks for metabolic activity rather than for a structure large enough to see.
Its value here is not simply knowing. It is that finding a single isolated site of recurrence can open up surgery as an option, whereas widespread disease points towards systemic treatment. Those are genuinely different plans, and establishing which situation you are in is a decision worth making on good information. See CA-125 monitoring and recurrence.
The classic situation. Something is happening and conventional imaging cannot say where.
Which sometimes localises disease too small or too diffuse for anatomical imaging to resolve.
A single site may be surgically treatable; widespread disease points to systemic treatment.
Small peritoneal deposits and mucinous tumours can be missed. It is read alongside markers and symptoms.
Most likely because it is not part of routine ovarian cancer staging, and that is a considered position rather than an omission. Ovarian cancer spreads as thin sheets and small nodules across the peritoneal surfaces, and PET has limited spatial resolution, so deposits below a few millimetres frequently do not register. Contrast CT shows anatomical detail and peritoneal thickening directly and performs better for exactly this pattern. The bowel also takes up glucose normally and sits throughout the abdomen, which makes the peritoneum a genuinely difficult area for PET to read.
Its strongest use is assessing suspected recurrence, particularly where a tumour marker is rising but conventional imaging is normal or equivocal — it can sometimes localise disease that anatomical imaging cannot resolve. It is also helpful in distinguishing active tumour from scar tissue, since scar is metabolically quiet, and in confirming whether an apparently isolated recurrence really is isolated, which determines whether surgery is a sensible option. It is not useful for characterising an ovarian mass, where ultrasound and MRI do the job far better.
Because it is central to the scan working rather than routine caution. The tracer is a form of glucose, and if your blood sugar is high, your own circulating glucose competes with the tracer for uptake — which reduces how much reaches tumour tissue and can make disease effectively invisible. Your blood glucose is checked before the injection and the scan may be postponed if it is too high. If you have diabetes, tell the department in advance so your medication and timing can be planned properly rather than sorted out on the day.
Because working muscles take up glucose. During the hour between injection and scanning, the tracer distributes through your body — and any muscle you are using takes it up avidly, producing bright areas on the images that can obscure or mimic disease. That is why you are asked not to talk, read, use your phone or move around. Warmth matters too: brown fat takes up glucose when you are cold, which is why departments keep the room warm. It is a dull hour, and following the instructions genuinely improves the quality of the scan.
Not necessarily. PET detects metabolic activity, and anything metabolically active lights up — infection, inflammation, tissue healing after surgery, and normal structures such as the bowel. This is why timing matters: a scan done soon after surgery or chemotherapy produces false positives from healing tissue and treatment effect. Reports often quote an SUV number describing uptake intensity, but there is no clean threshold separating cancer from inflammation. What matters is the pattern — where the uptake is, whether it matches an anatomical abnormality, and whether it fits the clinical picture.
It is reassuring but not conclusive, and the limitations are specific. PET has limited spatial resolution, so small peritoneal deposits — exactly the pattern in which ovarian cancer spreads — can be missed. Mucinous ovarian cancers often take up glucose poorly and may not light up despite active disease being present. So a quiet scan is read alongside your tumour markers, your symptoms and your other imaging rather than treated as a definitive all-clear. If your marker is rising or you have symptoms, those still count regardless of the PET result.
PET-CT is arranged through partner imaging centres and may be billed there — it is not delivered in-house at CION, and we state that upfront rather than leaving it to be discovered later. The first consultation is free and runs to about 45 minutes, and where PET-CT has been suggested the useful conversation is what specific question it is being asked to answer and whether it is the right test for it. Chemotherapy, maintenance therapy, genetic counselling and BRCA and HRD testing are delivered in-house across more than 35 centres; surgery is coordinated with specialist partner centres.